Our capabilities include generation, production, purification and analysis of viral vector-based products manufactured on mammalian cell lines.
Viral vectors are very attractive for product development, as they hold the promise of providing a platform to manufacture diverse products. For instance, a malaria vaccine, AIDS vaccine, or tuberculosis vaccine could be developed by inserting immunostimulatory genes from the Plasmodium falciparum parasite, the human immunodeficiency virus (HIV) or Mycobacterium tuberculosis bacteria, respectively, into a vector. However, for some vector systems, anti-vector immune responses must be taken into consideration; a viral vector product may elicit not only the intended immune response against the inserted target protein, but also an inadvertent response against the vector itself. This anti-vector immune response limits a repeat administration of the same viral vector product. For this reason, many viral vector products currently under development involve a combination of different viral vectors as part of a prime-boost vaccination strategy. For example, an adenoviral vector is used for priming, followed by the MVA used for a booster. These prime-boost regimens ensure long-term immunity and protection.
Viral vector track record
We have extensive experience in manufacturing a wide range of viral vectors including AAV, adenoviruses, lentiviruses, measles virus and VSV. We are proud to have manufactured viral vector-based gene therapy products as well as vaccine products for phase-I and phase-II clinical studies in both the EU and US markets. Our experience in the field, anchored in production, purification, and testing protocols, has resulted in a successful track record in delivering viral vector-based products. For example, in a collaboration with Prof. Frank Staal (Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Netherlands), we have delivered several lentiviral vector-based products for a candidate treatment for children suffering from Severed Combined Immuno-Deficiency (SCID). In addition, in collaboration with Prof. Andrew Baker (Centre for Cardiovascular Science, University of Edinburgh), we have successfully developed and manufactured novel adenoviral vectors for development of therapies against cardiovascular diseases. And together with IAVI, we are currently developing a VSV vector-based vaccine against Lassa fever.
Learn more about process development for viral vectors in our complete guide:
Viral vectors technologies
SCOUT® technology
The SCOUT® technology provides for an effective tool for “Design-of-Experiments” (DoE) approaches. It uses a miniaturized production and purification platform to rapidly develop multivariate processes.
SIDUS® technology
The SIDUS® platform combines our biological materials (cell lines and vector systems) with our in-depth experience and complete protocol systems for manufacturing viral vector-based vaccine, oncolytic and gene therapy products.
Process development
We develop scalable, robust and GMP-compliant manufacturing processes for viral vectors.
Upstream process development
We deliver scalable and robust GMP-compliant manufacturing processes for viral vectors. At Batavia Biosciences, we operate a range of different manufacturing scales and utilize diverse cell culture equipment for both adherent growth and growth in suspension.
Downstream process development
We deliver scalable and robust GMP-compliant processes for the purification of viral vectors. The different upstream process formats and scales are matched with appropriately scaled downstream equipment for clarification, concentration, chromatography and filtration.
Analytical development
We perform and develop all the required product-specific release and stability-determining assays for your viral vector product.
In silico cost modeling
When you are developing a viral vector product, such as vectored vaccines, gene therapies or oncolytic viruses, a robust, cost-effective, and high yielding manufacturing process will support your product’s financial viability.
Related resources
You’ve developed a candidate viral vaccine or viral vector product, and initial preclinical data are showing excellent efficacy. Now you’re ready to scale up for IND application and testing in…
Written by expert: Yang, Bioprocess Scientist In 2017, the New York Times wrote an article to report the critical shortage in the global viral vector manufacturing capacity. Next to the…
Written by expert: Ahd, Director Project Management Current costs of biopharmaceutical manufacturing often prevent segments of the world’s population from accessing critical medicines. Sometimes the costs even prevent medicines from…
Written by expert: Evert, Associate Director DSP With the first gene therapies now being on the market, the production quantities for gene therapy vectors are increasing to satisfy the demand.…
Talk to our experts
